Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ).
Shanghai Fosun Pharmaceutical announced that the National Medical Products Administration has accepted a drug registration application submitted by its subsidiary, Suzhou Erye Pharmaceutical, for Erythromycin Lactobionate for Injection. The chemical drug is intended for treating infections when oral administration is unsuitable or rapid high serum levels are required, as well as for preventing initial and recurrent attacks of rheumatic fever and bacterial endocarditis, with the group having invested about RMB6.33 million in its research and development to date, underscoring Fosun Pharma’s ongoing expansion of its anti-infective portfolio and potential to bolster its competitive standing in hospital-based injectable antibiotics.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a diversified Chinese healthcare company engaged in the research, development, manufacture and distribution of pharmaceutical products through a network of subsidiaries. The group focuses on both innovative and generic drugs for domestic and overseas markets, aiming to strengthen its position in the broader pharmaceutical industry value chain.
Average Trading Volume: 4,412,181
Technical Sentiment Signal: Buy
Current Market Cap: HK$77.52B
See more data about 2196 stock on TipRanks’ Stock Analysis page.